Please use this identifier to cite or link to this item:
Title: Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: A prospective randomized trial
Authors: Chung, A.Y.F.
Ooi, L.L.P.J.
Machin, D.
Tan, S.B. 
Goh, B.K.P.
Wong, J.S.
Chen, Y.M.
Li, P.C.N.
Gandhi, M.
Thng, C.H.
Yu, S.W.K.
Tan, B.S.
Lo, R.H.G.
Htoo, A.M.M.
Tay, K.H.
Sundram, F.X.
Goh, A.S.W.
Chew, S.P.
Liau, K.H.
Chow, P.K.H.
Tay, K.H.
Tan, Y.M.
Cheow, P.C.
Ho, C.K.
Soo, K.C.
Issue Date: Jun-2013
Citation: Chung, A.Y.F., Ooi, L.L.P.J., Machin, D., Tan, S.B., Goh, B.K.P., Wong, J.S., Chen, Y.M., Li, P.C.N., Gandhi, M., Thng, C.H., Yu, S.W.K., Tan, B.S., Lo, R.H.G., Htoo, A.M.M., Tay, K.H., Sundram, F.X., Goh, A.S.W., Chew, S.P., Liau, K.H., Chow, P.K.H., Tay, K.H., Tan, Y.M., Cheow, P.C., Ho, C.K., Soo, K.C. (2013-06). Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: A prospective randomized trial. World Journal of Surgery 37 (6) : 1356-1361. ScholarBank@NUS Repository.
Abstract: Background: The purpose of the present study was to determine whether intrahepatic injection of 131I-lipiodol (Lipiodol) is effective against recurrence of surgically resected hepatocellular carcinoma (HCC). Methods: From June 2001 through March 2007, this nationwide multi-center prospective randomized controlled trial enrolled 103 patients 4-6 weeks after curative resection of HCC with complete recovery (52: Lipiodol, 51: Control). Follow-up was every 3 months for 1 year, then every 6 months. Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively, both of which were evaluated by the Kaplan-Meier technique and summarized by the hazard ratio (HR). The design was based on information obtained from a similar trial that had been conducted in Hong Kong. Results: The Lipiodol group showed a small, and nonsignificant, improvement over control in RFS (HR = 0.75; 95 % confidence interval [95 % CI] 0.46-1.23; p = 0.25) and OS (HR = 0.88; 95 % CI 0.51-1.51; p = 0.64). Only two serious adverse events were reported, both with hypothyroidism caused by 131I-lipiodol and hepatic artery dissection during angiography. Conclusions: The randomized trial provides insufficient evidence to recommend the routine use of 131I-lipiodol in these patients. © 2013 Société Internationale de Chirurgie.
Source Title: World Journal of Surgery
ISSN: 03642313
DOI: 10.1007/s00268-013-1970-4
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Jan 17, 2020


checked on Jan 10, 2020

Page view(s)

checked on Jan 18, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.